Caladrius SEC Filing | Lisata Therapeutics, Inc.

Filing date	Form	Description	View
Mar 31, 2017	PREM14A	A preliminary proxy statement relating to a merger or acquisition	View HTML 0001571049-17-003097.pdf 0001571049-17-003097.rtf 0001571049-17-003097.xls
Mar 30, 2017	8-K	Report of unscheduled material events or corporate event	View HTML 0000320017-17-000027.pdf 0000320017-17-000027.rtf 0000320017-17-000027.xls
Mar 23, 2017	SC 13G/A	An amendment to the SC 13G filing	View HTML 0001104659-17-018804.pdf 0001104659-17-018804.rtf 0001104659-17-018804.xls
Mar 23, 2017	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001179110-17-005110.pdf 0001179110-17-005110.rtf 0001179110-17-005110.xls
Mar 23, 2017	8-K	Report of unscheduled material events or corporate event	View HTML 0000320017-17-000025.pdf 0000320017-17-000025.rtf 0000320017-17-000025.xls
Mar 22, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000023.pdf 0000320017-17-000023.rtf 0000320017-17-000023.xls
Mar 22, 2017	8-K	Report of unscheduled material events or corporate event	View HTML 0000320017-17-000022.pdf 0000320017-17-000022.rtf 0000320017-17-000022.xls
Mar 20, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0000320017-17-000017.pdf 0000320017-17-000017.rtf
Mar 17, 2017	DEFA14A	Additional proxy soliciting materials - definitive	View HTML 0001571049-17-002575.pdf 0001571049-17-002575.rtf 0001571049-17-002575.xls
Mar 17, 2017	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0000320017-17-000008.pdf 0000320017-17-000008.rtf 0000320017-17-000008.xls EX-101.INS - XBRL INSTANCE DOCUMENT